Related Experiment Videos
The effects of leukaemia inhibitory factor on platelet function
1Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Victoria, Australia.
British Journal of Haematology
|January 1, 1993
Summary
Leukaemia inhibitory factor (LIF) promotes platelet production and function. LIF-treated mice showed enhanced platelet counts and aggregation, suggesting therapeutic potential for thrombocytopenia.
Area of Science:
- Hematology
- Molecular Biology
- Biochemistry
Background:
- Leukaemia inhibitory factor (LIF) promotes megakaryocytopoiesis in vitro and increases platelet counts in vivo.
- LIF is a potential therapeutic agent for thrombocytopenia.
Purpose of the Study:
- To determine if platelets generated under LIF-stimulated megakaryocytopoiesis retain normal function.
- To assess platelet aggregation and thromboxane B2 release in LIF-treated mice.
Main Methods:
- Comparison of platelet aggregation and thromboxane B2 release in mice with constitutive or induced elevated LIF levels versus control mice.
- Measurement of platelet counts, platelet volumes, plasma fibrinogen, and calcium levels.
Main Results:
- Ex vivo platelet aggregability and thromboxane B2 release were intact and sometimes enhanced in LIF-treated mice.
- LIF-treated mice exhibited significantly increased platelet counts, larger platelet volumes, and elevated plasma fibrinogen and calcium levels.
- Platelet hyperreactivity in LIF-treated mice correlated with increased platelet volume and plasma fibrinogen levels.
Conclusions:
- Platelets produced under LIF stimulation maintain functional integrity.
- LIF treatment leads to increased platelet production and potential hyperreactivity, influenced by platelet volume and plasma factors like fibrinogen.
- LIF's role in stimulating acute-phase protein synthesis contributes to elevated fibrinogen levels.